Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine maintenance after response in intermediate/high-risk MDS and elderly AML
ChiCTR1900021030Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Remission rate, Bone marrow cell morphology and 1 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900021030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021030.